These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36993465)

  • 41. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
    Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses.
    Hulseberg CE; Fénéant L; Szymańska-de Wijs KM; Kessler NP; Nelson EA; Shoemaker CJ; Schmaljohn CS; Polyak SJ; White JM
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30700611
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever.
    Boisen ML; Hartnett JN; Shaffer JG; Goba A; Momoh M; Sandi JD; Fullah M; Nelson DKS; Bush DJ; Rowland MM; Heinrich ML; Koval AP; Cross RW; Barnes KG; Lachenauer AE; Lin AE; Nekoui M; Kotliar D; Winnicki SM; Siddle KJ; Gbakie M; Fonnie M; Koroma VJ; Kanneh L; Kulakosky PC; Hastie KM; Wilson RB; Andersen KG; Folarin OO; Happi CT; Sabeti PC; Geisbert TW; Saphire EO; Khan SH; Grant DS; Schieffelin JS; Branco LM; Garry RF
    Sci Rep; 2018 Apr; 8(1):5939. PubMed ID: 29651117
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques.
    Jiang J; Banglore P; Cashman KA; Schmaljohn CS; Schultheis K; Pugh H; Nguyen J; Humeau LM; Broderick KE; Ramos SJ
    Hum Vaccin Immunother; 2019; 15(9):2066-2074. PubMed ID: 31071008
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pathogenicity and virulence mechanisms of Lassa virus and its animal modeling, diagnostic, prophylactic, and therapeutic developments.
    Murphy HL; Ly H
    Virulence; 2021 Dec; 12(1):2989-3014. PubMed ID: 34747339
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serosurveillance of viral pathogens circulating in West Africa.
    O'Hearn AE; Voorhees MA; Fetterer DP; Wauquier N; Coomber MR; Bangura J; Fair JN; Gonzalez JP; Schoepp RJ
    Virol J; 2016 Oct; 13(1):163. PubMed ID: 27716429
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lassa virus diversity and feasibility for universal prophylactic vaccine.
    Lukashevich IS; Paessler S; de la Torre JC
    F1000Res; 2019; 8():. PubMed ID: 30774934
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity.
    Müller H; Fehling SK; Dorna J; Urbanowicz RA; Oestereich L; Krebs Y; Kolesnikova L; Schauflinger M; Krähling V; Magassouba N; Fichet-Calvet E; Ball JK; Kaufmann A; Bauer S; Becker S; von Messling V; Strecker T
    NPJ Vaccines; 2020; 5(1):71. PubMed ID: 32802410
    [No Abstract]   [Full Text] [Related]  

  • 49. Fluctuation of abundance and Lassa virus prevalence in Mastomys natalensis in Guinea, West Africa.
    Fichet-Calvet E; Lecompte E; Koivogui L; Soropogui B; Doré A; Kourouma F; Sylla O; Daffis S; Koulémou K; Ter Meulen J
    Vector Borne Zoonotic Dis; 2007; 7(2):119-28. PubMed ID: 17627428
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lethal Infection of Lassa Virus Isolated from a Human Clinical Sample in Outbred Guinea Pigs without Adaptation.
    Maruyama J; Manning JT; Mateer EJ; Sattler R; Bukreyeva N; Huang C; Paessler S
    mSphere; 2019 Sep; 4(5):. PubMed ID: 31554720
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The niche of One Health approaches in Lassa fever surveillance and control.
    Arruda LB; Haider N; Olayemi A; Simons D; Ehichioya D; Yinka-Ogunleye A; Ansumana R; Thomason MJ; Asogun D; Ihekweazu C; Fichet-Calvet E; Kock RA
    Ann Clin Microbiol Antimicrob; 2021 Apr; 20(1):29. PubMed ID: 33894784
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of Lassa virus in wild rodent feces: Implications for Lassa fever burden within households in the endemic region of Faranah, Guinea.
    Wood R; Bangura U; Mariën J; Douno M; Fichet-Calvet E
    One Health; 2021 Dec; 13():100317. PubMed ID: 34522759
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Space-Time Trends in Lassa Fever in Sierra Leone by ELISA Serostatus, 2012-2019.
    Shaffer JG; Schieffelin JS; Momoh M; Goba A; Kanneh L; Alhasan F; Gbakie M; Engel EJ; Bond NG; Hartnett JN; Nelson DKS; Bush DJ; Boisen ML; Heinrich ML; Rowland MM; Branco LM; Samuels RJ; Garry RF; Grant DS; The Viral Hemorrhagic Fever Consortium
    Microorganisms; 2021 Mar; 9(3):. PubMed ID: 33809204
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Data set on Lassa fever in post-conflict Sierra Leone.
    Shaffer JG; Schieffelin JS; Grant DS; Goba A; Momoh M; Kanneh L; Levy DC; Hartnett JN; Boisen ML; Branco LM; Garry RF;
    Data Brief; 2019 Apr; 23():103673. PubMed ID: 30788396
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lassa virus NP DEDDh 3'-5' exoribonuclease activity is required for optimal viral RNA replication and mutation control.
    Huang C; Mantlo E; Paessler S
    bioRxiv; 2023 Dec; ():. PubMed ID: 37090668
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lassa fever in Guinea: II. Distribution and prevalence of Lassa virus infection in small mammals.
    Demby AH; Inapogui A; Kargbo K; Koninga J; Kourouma K; Kanu J; Coulibaly M; Wagoner KD; Ksiazek TG; Peters CJ; Rollin PE; Bausch DG
    Vector Borne Zoonotic Dis; 2001; 1(4):283-97. PubMed ID: 12653128
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Animal Model of Sensorineural Hearing Loss Associated with Lassa Virus Infection.
    Yun NE; Ronca S; Tamura A; Koma T; Seregin AV; Dineley KT; Miller M; Cook R; Shimizu N; Walker AG; Smith JN; Fair JN; Wauquier N; Bockarie B; Khan SH; Makishima T; Paessler S
    J Virol; 2015 Dec; 90(6):2920-7. PubMed ID: 26719273
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccine platforms for the prevention of Lassa fever.
    Purushotham J; Lambe T; Gilbert SC
    Immunol Lett; 2019 Nov; 215():1-11. PubMed ID: 31026485
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunobiology of Ebola and Lassa virus infections.
    Prescott JB; Marzi A; Safronetz D; Robertson SJ; Feldmann H; Best SM
    Nat Rev Immunol; 2017 Mar; 17(3):195-207. PubMed ID: 28111475
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus.
    Cross RW; Fenton KA; Woolsey C; Prasad AN; Borisevich V; Agans KN; Deer DJ; Dobias NS; Fears AC; Heinrich ML; Geisbert JB; Garry RF; Branco LM; Geisbert TW
    Cell Rep Med; 2024 Feb; 5(2):101392. PubMed ID: 38280377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.